Our Reach

We are expanding access to quality healthcare by delivering essential medicines to emerging and underserved markets around the world.

Total Market Reach

Combining the available data, the pharmaceutical markets of South Africa, Egypt, Ghana, Iraq, and Yemen together represent a significant opportunity, reflecting strong demand and growth potential. When including Libya, the total market reach across these six countries becomes even more substantial, though precise figures are difficult to determine due to limited reporting.

Potential for Specific Medications

Our listed medications, including antibiotics (e.g., Amoxicillin, Ciprofloxacin), antihypertensives (e.g., Amlodipine), antidiabetics (e.g., Metformin), and NSAIDs (e.g., Ibuprofen, Meloxicam), are generally in demand across these markets due to the prevalence of infectious diseases, chronic conditions like hypertension and diabetes, and the need for pain management.

Designed for success

Entering the pharmaceutical markets of Iraq, Libya, Yemen, South Africa, Egypt, and Ghana offers significant opportunities, particularly in South Africa and Egypt, which have well-established and growing markets. The overall MENA region’s pharmaceutical industry is projected to grow substantially, indicating great opportunities.

Healthcare Realities in the Regions We Serve

The countries where Dawai Pharmaceuticals operates are home to millions of people, many living under challenging conditions where access to quality healthcare remains scarce. Despite their vibrant populations and growing demand for medical care, these regions face a combination of geopolitical instability, economic hardship, and systemic gaps in healthcare infrastructure.

SOUTH AFRICA

South Africa’s pharmaceutical market was valued at approximately $3.5 billion in 2018.

EGYPT

Egypt’s pharmaceutical market was valued at $3.8 billion in 2018, experiencing a growth rate of 26% over the previous year.

GHANA

Ghana’s pharmaceutical market was valued at approximately $400 million in 2021.

IRAQ

Iraq’s pharmaceutical market is projected to reach approximately $234.14 million by 2025, with oncology drugs being a significant contributor.

YEMEN

Yemen imported pharmaceutical products worth approximately $127.85 million in 2019.

LIBYA

Specific recent data for Libya’s pharmaceutical market is limited. However, the (MENA) region’s pharmaceutical industry is predicted to reach about $60 billion by 2025.

These regions collectively represent vast populations with significant unmet medical needs. At Dawai Pharmaceuticals, we see not just markets but people—families, children, and communities—who deserve access to life-saving treatments. Our mission is deeply philanthropic at its core: to bring hope and health to those who are too often overlooked, delivering medicines where they can make the greatest difference.